Resection for Hilar Cholangiocarcinoma: Analysis of Prognostic Factors and the Impact of Systemic Inflammation on Long-term Outcome
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Resection for hilar cholangiocarcinoma is the single hope for long-term survival.
Ninety patients underwent curative intent surgery for hilar cholangiocarcinoma between 1996 and 2012. The potential prognostic factors were assessed by univariate (Kaplan–Meier curves and log-rank test) and multivariate analyses (Cox proportional hazards model).
The median overall and disease-free survivals were 26 and 17 months, respectively. The multivariate analysis identified R0 resection (HR = 0.03, 95 % CI 0–0.19, p < 0.001), caudate lobe invasion (HR = 6.33, 95 % CI 1.31–30.46, p = 0.021), adjuvant gemcitabine-based chemotherapy (HR = 0.38, 95 % CI 0.15–0.94, p = 0.037), and the neutrophil-to-lymphocyte ratio (HR = 0.78, 95 % CI 0.62–0.98, p = 0.036) as independent prognostic factors for disease-free survival. The independent prognostic factors for overall survival were R0 resection (HR = 0.03, 95 % CI 0–0.22, p < 0.001), caudate lobe invasion (HR = 11.75, 95 % CI 1.65–83.33, p = 0.014), and adjuvant gemcitabine-based chemotherapy (HR = 0.19, 95 % CI 0.06–0.56, p = 0.003).
The negative resection margin represents the most important prognostic factor. Adjuvant gemcitabine-based chemotherapy appears to benefit survival. The neutrophil-to-lymphocyte ratio may potentially be used to stratify patients for future clinical trials.
- Resection for Hilar Cholangiocarcinoma: Analysis of Prognostic Factors and the Impact of Systemic Inflammation on Long-term Outcome
Journal of Gastrointestinal Surgery
Volume 17, Issue 5 , pp 913-924
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Hilar cholangiocarcinoma
- Industry Sectors